Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients With Type 2 Diabetes Mellitus

  • End date
    May 16, 2023
  • participants needed
  • sponsor
    First Affiliated Hospital of Jinan University
Updated on 17 February 2021


The purpose of this study is to assess the safety and efficacy of glucagon-like peptide-1 (GLP-1) analogue liraglutide in the treatment of acute minor stroke (National Institute of Health stroke scale, NIHSS 3) or high-risk transient ischemic attack (TIA) (ABCD2 score 4 ) patients with type 2 diabetes mellitus.


The treatment arm will receive the starting dose of liraglutide of 0.6mg/d subcutaneously once daily, and the dose will be increased to 1.8mg/d in two weeks, and then continue to administrate this dose for 90 days. The control arm will not use liraglutide. Other types of GLP-1 analogues or degraded by dipeptidyl peptidase-IV (DPP-IV) inhibitors will be prohibited. Study visits will be performed at day 7, day 303 and at 907 day.

Condition NIDDM, Diabetes Mellitus, Transient Ischemic Attack, Diabetes Mellitus, Type 2, Diabetes Prevention, Diabetes Mellitus Types I and II, Ischemic Stroke, Diabetes (Pediatric), Diabetes Mellitus Type 2, type 2 diabetes mellitus, type 2 diabetes, type ii diabetes, noninsulin-dependent diabetes mellitus, diabetes type 2, transient ischemic attacks
Treatment Liraglutide
Clinical Study IdentifierNCT03948347
SponsorFirst Affiliated Hospital of Jinan University
Last Modified on17 February 2021


Yes No Not Sure

Inclusion Criteria

Adult subjects (male or female 50 years)
Acute ischemic stroke patients (NIHSS 3 at the time of randomization) with type 2 diabetes mellitus within 24 hours of symptoms onset
High-risk TIA patients (ABCD2 score 4 at the time of randomization) with type 2 diabetes mellitus within 24 hours of onset
First stroke, or prior stroke without sequel (mRS score 1) and does not affect the NIHSS score
Informed consent signed

Exclusion Criteria

Diagnosis of hemorrhage brain disease on baseline head CT
Iatrogenic and cardiogenic stroke
Patients receiving thrombolysis or endovascular treatment
Use of a GLP-1 analogue or any dipeptidyl peptidase-IV (DPP-IV) inhibitor within the 3 months prior to screening
Family or personal history of multiple endocrine neoplasia type 2 (MEN2) or familial medullary thyroid carcinoma (FMTC)
Patients with pancreatitis or previous history of pancreatitis, inflammatory bowel disease and gastroparesis
Pregnant, lactating women,or patients who are likely to have a pregnancy and plan to have one
Allergic to liraglutide or excipients
Congestive heart failure (NYHA class III-IV)
Severe liver and kidney dysfunction (AST/ALT is 3 times higher than the normal upper limit, serum creatinine is 3 times higher than the normal upper limit)
Patients with malignant tumors who are expected to have a survival period of less than three months
Participated in other clinical trials of drugs within 3 months
Researchers believe that patients who are not suitable for this clinical study
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note